- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Acadia Pharmaceuticals Inc. Aktie
Verkaufen
Kaufen
Acadia Pharmaceuticals Inc. Chart
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Acadia Pharmaceuticals Inc. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
0,84 %
Intraday
-2,26 %
1 Woche
3,05 %
1 Monat
-46,12 %
Seit Jahresbeginn
-46,27 %
1 Jahr
-29,47 %
3 Jahre
-62,67 %
5 Jahre
-47,67 %
10 Jahre
Wikifolio
Passender Service zu Acadia Pharmaceuticals Inc.
Webinar zu Acadia Pharmaceuticals Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)14,150-32,590
- Jahrestief / Hoch ($)14,150-31,820
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Acadia Pharmaceuticals Inc.
Keine Dividenden verfügbar
Termine von Acadia Pharmaceuticals Inc.
- Mär3Acadia Pharmaceuticals Inc.Q4 2024 Earnings Release
- Mai13Acadia Pharmaceuticals Inc.Q1 2025 Earnings Release
- Jul30Acadia Pharmaceuticals Inc.Q2 2025 Earnings Release
Beschreibung
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
